Fresenius Kabi
Fresenius Kabi specializes in infusion therapies, intravenously administered drugs (IV drugs), and clinical nutrition for seriously and chronically ill patients in the hospital and out-patient environments. The company also is a leading supplier of medical devices and products in the area of transfusion technology.
| in million € |
2012 |
2011 |
Change in % |
| Sales |
4,539 |
3,964 |
15 |
| - thereof contribution to consolidated sales |
4,489 |
3,916 |
15 |
| - thereof intercompany sales |
50 |
48 |
4 |
| - contribution to consolidated sales |
23% |
24% |
|
| EBITDA |
1,101 |
955 |
15 |
| Depreciation and amortization |
167 |
152 |
10 |
| EBIT |
934 |
803 |
16 |
| Net interest |
-286 |
-278 |
-3 |
| Net income1 |
444 |
354 |
25 |
| Operating cash flow |
596 |
462 |
29 |
| Debt |
4,964 |
4,395 |
13 |
| Total assets |
8,662 |
7,282 |
19 |
| Capital expenditure |
276 |
177 |
56 |
| Acquisitions |
877 |
11 |
-- |
| Research and development expenses |
194 |
162 |
20 |
| Employees (per capita on balance sheet date) |
30,214 |
24,106 |
25 |
| Key figures | |||
| - EBITDA margin |
24,3% |
24.1% |
|
| - EBIT margin |
20,6% |
20.3% |
|
| - ROOA |
12,3% |
12.4% |
|
1 Net income attributable to Fresenius SE & Co. KGaA
